Can gender & genetics impact alectinib tox? @jtoonline.bsky.social
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer
Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.
www.jto.org
December 9, 2024 at 8:46 PM
Can gender & genetics impact alectinib tox? @jtoonline.bsky.social
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
- 215pts with ALK+ NSCLC
- women had ⬆️g3+ tox (f v m: 56% v 34% p=0.001), 35% had ⬆️trough levels p<0.001
- Pts with SNP affecting alectinib metabolism (PPAR-α 209G>A) had ⬆️g3+ tox
#Medsky #Oncsky #LCSM
www.jto.org/article/S155...
We’re sharing patient insights on ALK+ #lungcancer trtmt at #BTOG25.
Alectinib had the most side effects, Brigatinib the least. 30-45% on Lorlatinib reported visual, cognitive, or mood effects. When considering side effects alone, 71% chose Lorlatinib over Alectinib.
Real experiences matter. #LCSM
Alectinib had the most side effects, Brigatinib the least. 30-45% on Lorlatinib reported visual, cognitive, or mood effects. When considering side effects alone, 71% chose Lorlatinib over Alectinib.
Real experiences matter. #LCSM
March 3, 2025 at 5:10 PM
We’re sharing patient insights on ALK+ #lungcancer trtmt at #BTOG25.
Alectinib had the most side effects, Brigatinib the least. 30-45% on Lorlatinib reported visual, cognitive, or mood effects. When considering side effects alone, 71% chose Lorlatinib over Alectinib.
Real experiences matter. #LCSM
Alectinib had the most side effects, Brigatinib the least. 30-45% on Lorlatinib reported visual, cognitive, or mood effects. When considering side effects alone, 71% chose Lorlatinib over Alectinib.
Real experiences matter. #LCSM
Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC - Yvonne Diaz
@yvonnediaz.bsky.social
oncodaily.com/science/beva...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #ALK #Alectinib #Bevacizumab
@yvonnediaz.bsky.social
oncodaily.com/science/beva...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #ALK #Alectinib #Bevacizumab
Yvonne Diaz: Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC - OncoDaily
Nature Communications
oncodaily.com
May 19, 2025 at 8:15 PM
Combination of Alectinib and Bevacizumab Shows Promising Results in ALK+ NSCLC - Yvonne Diaz
@yvonnediaz.bsky.social
oncodaily.com/science/beva...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #ALK #Alectinib #Bevacizumab
@yvonnediaz.bsky.social
oncodaily.com/science/beva...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #ALK #Alectinib #Bevacizumab
#WCLC2025 - the E4512 trial tested 2 yrs of crizotinib after surgery for ALK+ #lungcancer vs observation. Result: no benefit. Trial stopped early as stronger drugs like alectinib became available. Today, adjuvant alectinib remains the standard of care. #LCSM
September 7, 2025 at 9:58 AM
#WCLC2025 - the E4512 trial tested 2 yrs of crizotinib after surgery for ALK+ #lungcancer vs observation. Result: no benefit. Trial stopped early as stronger drugs like alectinib became available. Today, adjuvant alectinib remains the standard of care. #LCSM
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
4/29 #TumorBoardTuesday
👩🏫Mini tweetorial 3👨🏫
🤚Resectable ALKr NSCLC?
🎯ALINA ⬇️
⭐️Phase III Trial of Adjuvant Alectinib
⭐️Stage IB-IIIA (AJCC 7th ed) ALKr NSCLC
💊Adjuvant alectinib 600mg BID x 2 yrs vs chemo
👀Med DFS NR vs 41.3 mo
🏆Adjuvant alectinib FDA approved/SOC
👩🏫Mini tweetorial 3👨🏫
🤚Resectable ALKr NSCLC?
🎯ALINA ⬇️
⭐️Phase III Trial of Adjuvant Alectinib
⭐️Stage IB-IIIA (AJCC 7th ed) ALKr NSCLC
💊Adjuvant alectinib 600mg BID x 2 yrs vs chemo
👀Med DFS NR vs 41.3 mo
🏆Adjuvant alectinib FDA approved/SOC
December 11, 2024 at 1:11 AM
4/29 #TumorBoardTuesday
👩🏫Mini tweetorial 3👨🏫
🤚Resectable ALKr NSCLC?
🎯ALINA ⬇️
⭐️Phase III Trial of Adjuvant Alectinib
⭐️Stage IB-IIIA (AJCC 7th ed) ALKr NSCLC
💊Adjuvant alectinib 600mg BID x 2 yrs vs chemo
👀Med DFS NR vs 41.3 mo
🏆Adjuvant alectinib FDA approved/SOC
👩🏫Mini tweetorial 3👨🏫
🤚Resectable ALKr NSCLC?
🎯ALINA ⬇️
⭐️Phase III Trial of Adjuvant Alectinib
⭐️Stage IB-IIIA (AJCC 7th ed) ALKr NSCLC
💊Adjuvant alectinib 600mg BID x 2 yrs vs chemo
👀Med DFS NR vs 41.3 mo
🏆Adjuvant alectinib FDA approved/SOC
Alectinib + bevacizumab.
A new trial shows this combo may help slow ALK+ #lungcancer & protect the brain.
It’s from the ALEK-B study (Phase II, 41 people)
Strong CNS activity, well tolerated
Not approved in the UK yet
More here 👉 fondazionebonadonna.org/en/alectinib...
A new trial shows this combo may help slow ALK+ #lungcancer & protect the brain.
It’s from the ALEK-B study (Phase II, 41 people)
Strong CNS activity, well tolerated
Not approved in the UK yet
More here 👉 fondazionebonadonna.org/en/alectinib...
Alectinib plus bevacizumab in ALK-rearranged non-small cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
July 8, 2025 at 7:33 AM
Alectinib + bevacizumab.
A new trial shows this combo may help slow ALK+ #lungcancer & protect the brain.
It’s from the ALEK-B study (Phase II, 41 people)
Strong CNS activity, well tolerated
Not approved in the UK yet
More here 👉 fondazionebonadonna.org/en/alectinib...
A new trial shows this combo may help slow ALK+ #lungcancer & protect the brain.
It’s from the ALEK-B study (Phase II, 41 people)
Strong CNS activity, well tolerated
Not approved in the UK yet
More here 👉 fondazionebonadonna.org/en/alectinib...
Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.
Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer
Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer
May 18, 2025 at 11:30 AM
Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.
Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer
Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
ascopubs.org
November 19, 2024 at 2:20 AM
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Nice to see attention called to weight gain adverse effect of alectinib for patients with ALK positive NSCLC. It's a very real problem and, as noted, we don't capture this very well in clinical trials. ascopubs.org/doi/full/10....
December 12, 2024 at 1:27 PM
Nice to see attention called to weight gain adverse effect of alectinib for patients with ALK positive NSCLC. It's a very real problem and, as noted, we don't capture this very well in clinical trials. ascopubs.org/doi/full/10....
Hastaların 449'u Crizotinib, 417'si Alectinib, 36'sı Lorlatinib, 30'u Brigatinib ve 8'i Ceritinib tedavisi aldı. Araştırma sonuçlarına göre Alectinib, 46,5 aylık ortalama hayatta kalma süresi ve 33,5 aylık tedavide kalma süresiyle en net avantajı sağlayan ilaç olarak öne çıktı.
May 19, 2026 at 2:33 PM
Hastaların 449'u Crizotinib, 417'si Alectinib, 36'sı Lorlatinib, 30'u Brigatinib ve 8'i Ceritinib tedavisi aldı. Araştırma sonuçlarına göre Alectinib, 46,5 aylık ortalama hayatta kalma süresi ve 33,5 aylık tedavide kalma süresiyle en net avantajı sağlayan ilaç olarak öne çıktı.
Final ALEX trial results just shared at #ESMO25 show median overall survival of 81 months with first-line alectinib for ALK+ #lungcancer.
Nearly half were alive at 7 years - a huge shift from a decade ago. Crizotinib is no longer used first-line in the UK.
#LCSM
Nearly half were alive at 7 years - a huge shift from a decade ago. Crizotinib is no longer used first-line in the UK.
#LCSM
October 18, 2025 at 9:24 AM
Final ALEX trial results just shared at #ESMO25 show median overall survival of 81 months with first-line alectinib for ALK+ #lungcancer.
Nearly half were alive at 7 years - a huge shift from a decade ago. Crizotinib is no longer used first-line in the UK.
#LCSM
Nearly half were alive at 7 years - a huge shift from a decade ago. Crizotinib is no longer used first-line in the UK.
#LCSM
Could alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
September 17, 2026 at 8:04 AM
Could alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
#WCLC26 #ALKPositive #LCSM
First presentation of Phase 3 ALKAZAR trial at #ASCO25 @drsanjaypopat.bsky.social
Next step from Nuvalent’s ALKOVE-1 study:
neladalkib vs alectinib in 1st-line advanced ALK+ #lungcancer.
Still enrolling - if it delivers, could shake up trtmt improving brain coverage & reducing side effects. #LCSM
Next step from Nuvalent’s ALKOVE-1 study:
neladalkib vs alectinib in 1st-line advanced ALK+ #lungcancer.
Still enrolling - if it delivers, could shake up trtmt improving brain coverage & reducing side effects. #LCSM
May 26, 2025 at 8:44 AM
First presentation of Phase 3 ALKAZAR trial at #ASCO25 @drsanjaypopat.bsky.social
Next step from Nuvalent’s ALKOVE-1 study:
neladalkib vs alectinib in 1st-line advanced ALK+ #lungcancer.
Still enrolling - if it delivers, could shake up trtmt improving brain coverage & reducing side effects. #LCSM
Next step from Nuvalent’s ALKOVE-1 study:
neladalkib vs alectinib in 1st-line advanced ALK+ #lungcancer.
Still enrolling - if it delivers, could shake up trtmt improving brain coverage & reducing side effects. #LCSM
Similar-ish in action to the Alectinib that I take. I almost died without it. Small lung cancer can rip your lungs apart and you bleed out
Alectinib is expensive, so maybe this competition will bring down the prices
The NHS is a great institution and we should invest in biotechnology
Alectinib is expensive, so maybe this competition will bring down the prices
The NHS is a great institution and we should invest in biotechnology
Cuba is First in the World to Invent a Lung Cancer Vaccine Despite Decades of Sanctions and Blockade.
hrnews1.substack.com/p/cuba-is-fi... -
hrnews1.substack.com/p/cuba-is-fi... -
Cuba is First in the World to Invent a Lung Cancer Vaccine Despite Decades of Sanctions and Blockade
The U.S. is Actively Starving a Country Who is Trying to Cure Cancer
hrnews1.substack.com
July 11, 2026 at 3:42 PM
Similar-ish in action to the Alectinib that I take. I almost died without it. Small lung cancer can rip your lungs apart and you bleed out
Alectinib is expensive, so maybe this competition will bring down the prices
The NHS is a great institution and we should invest in biotechnology
Alectinib is expensive, so maybe this competition will bring down the prices
The NHS is a great institution and we should invest in biotechnology
At #WCLC2025, the NAUTIKA1 study showed the impact of giving alectinib before surgery in early-stage ALK+ #lungcancer:
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
September 9, 2025 at 5:19 PM
At #WCLC2025, the NAUTIKA1 study showed the impact of giving alectinib before surgery in early-stage ALK+ #lungcancer:
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
60.7% major pathological response, 25% complete response, 63% radiographic responses after just 8 weeks.
Surgery still needed - and it all starts with biomarker testing! #LCSM
Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC @ascocancer.bsky.social #ASCO25 #lcsm #oncology
www.onclive.com/view/neoadju...
www.onclive.com/view/neoadju...
Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC
Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.
www.onclive.com
June 2, 2025 at 3:31 PM
Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC @ascocancer.bsky.social #ASCO25 #lcsm #oncology
www.onclive.com/view/neoadju...
www.onclive.com/view/neoadju...
My monthly prescription to Alectinib, a targeted therapy for lung cancer patients, would cost me about 17k a month, were it not for insurance. How's that for budget friendly?
May 8, 2025 at 7:12 PM
My monthly prescription to Alectinib, a targeted therapy for lung cancer patients, would cost me about 17k a month, were it not for insurance. How's that for budget friendly?
Real-world data has confirmed what trials suggested: for people with ALK+ #lungcancer, alectinib’s survival advantage over crizotinib holds up outside clinical trials. 940 patients. Lorlatinib showed a promising trend vs alectinib, but only 36 pts.
www.lungcancerjournal.info/article/S016... #LCSM
www.lungcancerjournal.info/article/S016... #LCSM
May 12, 2026 at 3:28 PM
Real-world data has confirmed what trials suggested: for people with ALK+ #lungcancer, alectinib’s survival advantage over crizotinib holds up outside clinical trials. 940 patients. Lorlatinib showed a promising trend vs alectinib, but only 36 pts.
www.lungcancerjournal.info/article/S016... #LCSM
www.lungcancerjournal.info/article/S016... #LCSM
I went through Chemo, a lower left lobectomy, radiation, and now I am on alectinib, which is not my friend. I tried to go back to work part time, I got covid. I was sick for 2 months. That is when I thought what the fudge? I knew I couldn't work anymore, my daily reminder. I love my job.
December 20, 2024 at 11:50 PM
I went through Chemo, a lower left lobectomy, radiation, and now I am on alectinib, which is not my friend. I tried to go back to work part time, I got covid. I was sick for 2 months. That is when I thought what the fudge? I knew I couldn't work anymore, my daily reminder. I love my job.
Are we heading towards combo treatment in #ALKPositive #lungcancer?
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature Communications
Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy. This work reports a phase 2 trial investigating w...
www.nature.com
May 18, 2025 at 9:34 AM
Are we heading towards combo treatment in #ALKPositive #lungcancer?
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
Alectinib + bevacizumab showed “durable disease control” at 3 years in the ALEK-B trial, just published in Nature Communications
Raises new questions about how to delay resistance.
🔗 www.nature.com/articles/s41...
#NSCLC #LCSM
New ESMO Open (2025) study looked at ctDNA in ALK+ #lungcancer.
Liquid biopsy picked up resistance to alectinib in some people - linked to shorter time before progression.
Other early signals included KRAS and NRAS changes.
🔗 pubmed.ncbi.nlm.nih.gov/40912045/
#LCSM
Liquid biopsy picked up resistance to alectinib in some people - linked to shorter time before progression.
Other early signals included KRAS and NRAS changes.
🔗 pubmed.ncbi.nlm.nih.gov/40912045/
#LCSM
September 20, 2025 at 6:12 AM
New ESMO Open (2025) study looked at ctDNA in ALK+ #lungcancer.
Liquid biopsy picked up resistance to alectinib in some people - linked to shorter time before progression.
Other early signals included KRAS and NRAS changes.
🔗 pubmed.ncbi.nlm.nih.gov/40912045/
#LCSM
Liquid biopsy picked up resistance to alectinib in some people - linked to shorter time before progression.
Other early signals included KRAS and NRAS changes.
🔗 pubmed.ncbi.nlm.nih.gov/40912045/
#LCSM
The ALKAZAR Phase 3 trial has officially begun - testing neladalkib (NVL-655) vs alectinib in newly diagnosed ALK+ #LungCancer.
Neladalkib is a brain-penetrant, ALK-selective inhibitor designed to spare TRK - which may reduce CNS-related side effects.
Could lead to better 1L option for ALK+. #LCSM
Neladalkib is a brain-penetrant, ALK-selective inhibitor designed to spare TRK - which may reduce CNS-related side effects.
Could lead to better 1L option for ALK+. #LCSM
July 23, 2025 at 5:50 AM
The ALKAZAR Phase 3 trial has officially begun - testing neladalkib (NVL-655) vs alectinib in newly diagnosed ALK+ #LungCancer.
Neladalkib is a brain-penetrant, ALK-selective inhibitor designed to spare TRK - which may reduce CNS-related side effects.
Could lead to better 1L option for ALK+. #LCSM
Neladalkib is a brain-penetrant, ALK-selective inhibitor designed to spare TRK - which may reduce CNS-related side effects.
Could lead to better 1L option for ALK+. #LCSM
I am extraordinarily lucky to be in a position where, having just started alectinib, I’m good for a while and likely won’t need to worry about changing anything up. But this is precisely the kind of shit that has me furious and terrified.
Freezing scientific funding isn’t abstract. In medicine, life or death is often dictated by time. Temporary delays can cause great harm.
January 25, 2025 at 1:22 AM
I am extraordinarily lucky to be in a position where, having just started alectinib, I’m good for a while and likely won’t need to worry about changing anything up. But this is precisely the kind of shit that has me furious and terrified.